# A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

> **NCT04712643** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 342 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Becavizumab
- **DEVICE:** Transarterial chemoembolization (TACE)

## Key facts

- **NCT ID:** NCT04712643
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-12
- **Primary completion:** 2029-02-01
- **Final completion:** 2029-02-01
- **Target enrollment:** 342 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04712643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04712643, "A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04712643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*